• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
OTC Pharmaceuticals in Switzerland - Product Image

OTC Pharmaceuticals in Switzerland

  • ID: 2113059
  • September 2014
  • Region: Switzerland
  • 39 pages
  • MarketLine

Introduction

OTC Pharmaceuticals in Switzerland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Switzerland otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights:

- The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters READ MORE >

Note: Product cover images may vary from those shown

Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market share
Market distribution
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Bayer AG
GlaxoSmithKline Plc
Johnson & Johnson
Novartis AG
Macroeconomic Indicators
Country Data
Appendix
Methodology
Industry associations
Related research

LIST OF TABLES
Table 1: Switzerland OTC pharmaceuticals market value: $ million, 2009–13
Table 2: Switzerland OTC pharmaceuticals market category segmentation: $ million, 2013
Table 3: Switzerland OTC pharmaceuticals market geography segmentation: $ million, 2013
Table 4: Switzerland OTC pharmaceuticals market share: % share, by value, 2013
Table 5: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2013
Table 6: Switzerland OTC pharmaceuticals market value forecast: $ million, 2013–18
Table 7: Bayer AG: key facts
Table 8: Bayer AG: key financials ($)
Table 9: Bayer AG: key financials (€)
Table 10: Bayer AG: key financial ratios
Table 11: GlaxoSmithKline Plc: key facts
Table 12: GlaxoSmithKline Plc: key financials ($)
Table 13: GlaxoSmithKline Plc: key financials (£)
Table 14: GlaxoSmithKline Plc: key financial ratios
Table 15: Johnson & Johnson: key facts
Table 16: Johnson & Johnson: key financials ($)
Table 17: Johnson & Johnson: key financial ratios
Table 18: Novartis AG: key facts
Table 19: Novartis AG: key financials ($)
Table 20: Novartis AG: key financial ratios
Table 21: Switzerland size of population (million), 2009–13
Table 22: Switzerland gdp (constant 2005 prices, $ billion), 2009–13
Table 23: Switzerland gdp (current prices, $ billion), 2009–13
Table 24: Switzerland inflation, 2009–13
Table 25: Switzerland consumer price index (absolute), 2009–13
Table 26: Switzerland exchange rate, 2009–13

LIST OF FIGURES
Figure 1: Switzerland OTC pharmaceuticals market value: $ million, 2009–13
Figure 2: Switzerland OTC pharmaceuticals market category segmentation: % share, by value, 2013
Figure 3: Switzerland OTC pharmaceuticals market geography segmentation: % share, by value, 2013
Figure 4: Switzerland OTC pharmaceuticals market share: % share, by value, 2013
Figure 5: Switzerland OTC pharmaceuticals market distribution: % share, by value, 2013
Figure 6: Switzerland OTC pharmaceuticals market value forecast: $ million, 2013–18
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Switzerland, 2013
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Switzerland, 2013
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Switzerland, 2013
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Switzerland, 2013
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Switzerland, 2013
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Switzerland, 2013
Figure 13: Bayer AG: revenues & profitability
Figure 14: Bayer AG: assets & liabilities
Figure 15: GlaxoSmithKline Plc: revenues & profitability
Figure 16: GlaxoSmithKline Plc: assets & liabilities
Figure 17: Johnson & Johnson: revenues & profitability
Figure 18: Johnson & Johnson: assets & liabilities
Figure 19: Novartis AG: revenues & profitability
Figure 20: Novartis AG: assets & liabilities

Note: Product cover images may vary from those shown

Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson and Novartis AG

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos